EPIRUS Biopharmaceuticals, Inc. (EPRS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
699 BOYLSTON ST BOSTON, MA 02116 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2016 MRQ | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 31,515 | 21,462 | 17,958 | 4,531 | |||
| Cash and cash equivalents | 31,515 | 21,462 | 17,958 | 4,531 | |||
| Receivables | 2,511 | 3,045 | |||||
| Prepaid expense | 668 | 633 | ✕ | ||||
| Other current assets | 653 | 461 | ✕ | ||||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | 684 | ||
| Other undisclosed current assets | 2,411 | 462 | 273 | 30,109 | |||
| Total current assets: | 35,247 | 23,018 | 20,742 | 38,369 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 2,073 | 704 | 2,363 | 3,535 | |||
| Intangible assets, net (including goodwill) | 32,771 | 21,863 | 7,200 | 17,654 | |||
| Goodwill | 26,361 | 16,363 | |||||
| Intangible assets, net (excluding goodwill) | 6,410 | 5,500 | 7,200 | 17,654 | |||
| Restricted cash and investments | 1,924 | 1,825 | 1,801 | 1,817 | |||
| Other noncurrent assets | 249 | 374 | ✕ | ||||
| Other undisclosed noncurrent assets | 3,605 | ||||||
| Total noncurrent assets: | 37,017 | 28,371 | 11,364 | 23,006 | |||
| TOTAL ASSETS: | 72,264 | 51,389 | 32,106 | 61,375 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 7,032 | 7,899 | 6,232 | 9,798 | |||
| Settlement liabilities | 978 | ✕ | ✕ | ||||
| Interest and dividends payable | 71 | ||||||
| Employee-related liabilities | 1,244 | 656 | 1,696 | ||||
| Accounts payable | 2,051 | 2,483 | 2,237 | 3,261 | |||
| Accrued liabilities | 4,003 | 4,101 | 3,339 | 4,841 | |||
| Debt | 14,833 | 6,640 | 12,822 | ||||
| Other liabilities | 343 | 557 | |||||
| Deferred revenue and credits | 957 | 50 | 2,392 | 4,918 | |||
| Deferred tax liabilities | 185 | 185 | |||||
| Other undisclosed current liabilities | 9,931 | (1,315) | (372) | (7,907) | |||
| Total current liabilities: | 33,281 | 7,376 | 14,892 | 19,631 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 7,282 | 2,132 | 8,772 | ||||
| Long-term debt, excluding current maturities | 7,282 | 2,132 | 8,772 | ||||
| Liabilities, other than long-term debt | 1,967 | 2,164 | 309 | 1,071 | |||
| Deferred revenue and credits | 1,173 | 946 | 309 | 1,057 | |||
| Deferred tax liabilities, net | 369 | 553 | |||||
| Other liabilities | 425 | 665 | 14 | ||||
| Other undisclosed noncurrent liabilities | 648 | ||||||
| Total noncurrent liabilities: | 2,615 | 9,446 | 2,441 | 9,843 | |||
| Total liabilities: | 35,896 | 16,822 | 17,333 | 29,474 | |||
| Equity | |||||||
| Equity, attributable to parent | 36,368 | 32,401 | 14,182 | 31,026 | |||
| Common stock | 24 | 13 | 26 | 127 | |||
| Additional paid in capital | 175,126 | 118,959 | 393,796 | 371,912 | |||
| Accumulated other comprehensive income (loss) | (23) | 10 | |||||
| Accumulated deficit | (138,759) | (86,571) | (379,640) | (341,023) | |||
| Total equity: | 36,368 | 32,401 | 14,182 | 31,026 | |||
| Other undisclosed liabilities and equity | 2,166 | 591 | 875 | ||||
| TOTAL LIABILITIES AND EQUITY: | 72,264 | 51,389 | 32,106 | 61,375 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 701 | 4 | 14,731 | 12,550 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (125) | |||||
| Gross profit: | 576 | 4 | 14,731 | 12,550 | ||
| Operating expenses | (52,876) | (39,259) | (51,941) | (55,386) | ||
| Operating loss: | (52,300) | (39,255) | (37,210) | (42,836) | ||
| Nonoperating income (expense) | (432) | (2,632) | 60 | 241 | ||
| Investment income, nonoperating | 46 | 150 | ||||
| Other nonoperating income (expense) | (116) | 262 | 14 | 91 | ||
| Interest and debt expense | (22) | (1,467) | (2,173) | |||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 22 | |||||
| Loss from continuing operations before income taxes: | (52,732) | (41,887) | (38,617) | (44,768) | ||
| Income tax benefit | 544 | 43 | 441 | |||
| Loss from continuing operations: | (52,188) | (41,844) | (38,617) | (44,327) | ||
| Loss before gain (loss) on sale of properties: | (52,188) | (41,844) | (38,617) | (44,327) | ||
| Net loss available to common stockholders, diluted: | (52,188) | (41,844) | (38,617) | (44,327) | ||
Comprehensive Income ($ in thousands)
| 3/31/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Net loss: | (52,188) | (41,844) | (38,617) | (44,327) | ||
| Comprehensive loss: | (52,188) | (41,844) | (38,617) | (44,327) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (23) | (10) | 18 | |||
| Comprehensive loss, net of tax, attributable to parent: | (52,211) | (41,844) | (38,627) | (44,309) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.